Observation vs Progesterone Treatment for Management of Uterine Arteriovenous Malformation

• Status: Not yet recruiting
• Trial end date: 2024-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

A randomized trial which compares conservative management to progesterone based treatment for arteriovenous malformation

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: HaEmek Medical Center, Israel
• Treatments: Medroxyprogesterone; Medroxyprogesterone Acetate

Criteria

Inclusion Criteria:

• women between age of 18 to 50, diagnosed with AVM

• hemodynamically stable at clinical presentation

Exclusion Criteria:

• unstable patients

• contraindication to treatment

• US examination not in the US department